X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (320) 320
humans (287) 287
male (218) 218
gastroenterology & hepatology (215) 215
female (212) 212
adult (186) 186
middle aged (174) 174
hepatitis c, chronic - drug therapy (106) 106
antiviral agents - therapeutic use (94) 94
hepatitis c (91) 91
aged (83) 83
treatment outcome (83) 83
genotype (82) 82
drug therapy, combination (80) 80
gastroenterology and hepatology (76) 76
interferon-alpha - therapeutic use (69) 69
hepacivirus - genetics (66) 66
ribavirin - therapeutic use (66) 66
ribavirin (65) 65
interferon (60) 60
hepatitis c virus (56) 56
polyethylene glycols - therapeutic use (56) 56
adolescent (55) 55
therapy (48) 48
recombinant proteins (47) 47
abridged index medicus (46) 46
care and treatment (45) 45
hepatitis (44) 44
virus-infection (43) 43
viral load (42) 42
genetic aspects (40) 40
antiviral agents - administration & dosage (39) 39
cirrhosis (39) 39
hepatitis c, chronic - virology (39) 39
liver (39) 39
interferon-alpha - administration & dosage (37) 37
ribavirin - administration & dosage (37) 37
young adult (37) 37
rna, viral - blood (36) 36
analysis (35) 35
mutation (35) 35
chronic hepatitis-c (34) 34
diagnosis (34) 34
health aspects (34) 34
hepatolenticular degeneration - genetics (33) 33
medicine, general & internal (33) 33
hepacivirus - drug effects (32) 32
liver - pathology (32) 32
retrospective studies (32) 32
sustained virological response (31) 31
antiviral agents - adverse effects (30) 30
follow-up studies (30) 30
hepatitis c, chronic - complications (30) 30
plus ribavirin (30) 30
prospective studies (29) 29
recombinant proteins - therapeutic use (29) 29
animals (28) 28
infectious diseases (28) 28
ribavirin - adverse effects (28) 28
infection (27) 27
liver cirrhosis (27) 27
prognosis (27) 27
human necessities (26) 26
hygiene (26) 26
polyethylene glycols - administration & dosage (26) 26
time factors (26) 26
child (25) 25
chronic hepatitis c (25) 25
hepatolenticular degeneration - diagnosis (25) 25
interferon-alpha - adverse effects (25) 25
medical or veterinary science (25) 25
pharmacology & pharmacy (25) 25
predictive value of tests (25) 25
preparations for medical, dental, or toilet purposes (25) 25
virology (25) 25
biological response modifiers (24) 24
liver transplantation (24) 24
interleukins - genetics (23) 23
liver - metabolism (23) 23
specific therapeutic activity of chemical compounds ormedicinal preparations (23) 23
drug therapy (22) 22
gene (22) 22
hepatitis c - drug therapy (22) 22
medical colleges (22) 22
peginterferon alpha-2a (22) 22
adenosine triphosphatases - genetics (21) 21
antiviral agents (21) 21
combination therapy (21) 21
copper (21) 21
dose-response relationship, drug (21) 21
hepacivirus - isolation & purification (21) 21
liver diseases (21) 21
polymerase chain reaction (21) 21
recurrence (21) 21
risk factors (21) 21
telaprevir (21) 21
biopsy (20) 20
copper - metabolism (20) 20
copper-transporting atpases (20) 20
genotype & phenotype (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (587) 587
German (22) 22
French (16) 16
Hungarian (11) 11
Spanish (4) 4
Slovak (3) 3
Polish (2) 2
Danish (1) 1
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Infectious Diseases, ISSN 1473-3099, 10/2017, Volume 17, Issue 10, pp. 1008 - 1009
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/S1473-3099(17)30486-3 Byline: Peter Ferenci (a) 
INFECTIOUS DISEASES | SOFOSBUVIR | Hepatitis C virus | Drug therapy, Combination | Antiretroviral drugs | Genotype & phenotype | Hepatitis | Liver diseases | Gastroenterology | Infections | Interferon | Patients | Index Medicus
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 05/2014, Volume 1315, Issue 1, pp. 1 - 5
Journal Article
Clinical Liver Disease, ISSN 2046-2484, 01/2016, Volume 7, Issue 1, pp. 8 - 10
Watch a video presentation of this article Watch the interview with the author 
Journal Article
Nature Reviews Gastroenterology & Hepatology, ISSN 1759-5045, 01/2015, Volume 12, Issue 1, pp. 10 - 11
The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir-ribavirin with or... 
Journal Article
Journal of Hepatology, ISSN 0168-8278, 07/2019, Volume 71, Issue 1, pp. 222 - 224
Journal Article
Hepatology, ISSN 0270-9139, 04/2019, Volume 69, Issue 4, pp. 1464 - 1476
Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being... 
Adolescence | Phenotypes | Liver diseases | Nucleotide sequence | Mental disorders | Neurological diseases | Cirrhosis | Gene frequency | Biopsy | Children | Mutation | Diagnosis | Females | Wilson's disease | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1993 - 2001
Journal Article
Gastroenterology Report, 5/2017, Volume 5, Issue 2, pp. 138 - 147
Hepatic encephalopathy (HE) is a reversible syndrome of impaired brain function occurring in patients with advanced liver diseases. The precise pathophysiology... 
diagnostic tests | management strategy | pathophysiology | Review | Hepatic encephalopathy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article